MICHAEL J. BERENDT, PH.D. - Corporate Board Profile

WATERS CORP /DE/

Filing Date	Source Excerpt
2013-03-29	Michael J. Berendt, Ph.D., 64, has served as a Director of the Company since March 1998. Dr. Berendt is an independent director and investor. The Nominating and Corporate Governance Committee currently consists of Dr. Michael J. Berendt (Chair). Director compensation in 2012 was $301,630.
2014-04-04	Michael J. Berendt, Ph.D., 65, has served as a Director of the Company since March 1998. The Nominating and Corporate Governance Committee currently consists of Dr. Michael J. Berendt (Chair). The director compensation table shows his total compensation as $304,325 for 2013.
2015-04-01	Michael J. Berendt, Ph.D., 66, has served as a Director of the Company since March 1998. ... The Nominating and Corporate Governance Committee currently consists of Dr. Michael J. Berendt (Chair), Dr. Laurie H. Glimcher, and Mr. Thomas P. Salice.
2016-04-01	Michael J. Berendt, Ph.D., 67, has served as a Director of the Company since March 1998. Dr. Berendt is the Chief Executive Officer and Chief Scientist of Telesta Therapeutics, a position he assumed in November 2013. From July 2011 to November 2013, Dr. Berendt was a Life Sciences Consultant. From March 2006 to July 2011, Dr. Berendt served as the President and Chief Executive Officer of Aegera Therapeutics Inc. From August 2004 to December 2005, Dr. Berendt served as Managing Director of Research Corporation Technologies. From November 2000 to August 2004, Dr. Berendt served as Managing Director of AEA Investors. Dr. Berendt also worked for 18 years, from 1982 to 2000, in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc. Dr. Berendt is a director of Telesta Therapeutics Inc. Dr. Berendt has served as a director of Onyx Pharmaceuticals, Myriad Genetics, Inc., Catalyst Biosciences and Northstar Neuroscience. Dr. Berendt's experience in the pharmaceutical industry both from a management and a scientific perspective provides unique technical insight to the Waters Board. The Nominating and Corporate Governance Committee currently consists of Dr. Michael J. Berendt (Chair), Dr. Laurie H. Glimcher, and Mr. Thomas P. Salice.
2017-03-29	Dr. Berendt, 68, has served as a Director of the Company since March 1998. Since December 2016, Dr. Berendt has been a life sciences industry consultant. From November 2013 to November 2016, Dr. Berendt was the Chief Executive Officer and Chief Scientist of Telesta Therapeutics. From July 2011 to November 2013, Dr. Berendt was a life sciences industry consultant. From March 2006 to July 2011, Dr. Berendt served as the President and Chief Executive Officer of Aegera Therapeutics Inc. From August 2004 to December 2005, Dr. Berendt served as Managing Director of Research Corporation Technologies, Inc. From November 2000 to August 2004, Dr. Berendt served as Managing Director of AEA Investors LP. Dr. Berendt also worked for 18 years, from 1982 to 2000, in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc. Waters Committee Memberships Nominating and Corporate Governance Committee (Chair) Other Current Public Company Boards None Former Public Company Directorships Held in the Past Five Years Onyx Pharmaceuticals, Inc. Myriad Genetics, Inc. Catalyst Biosciences, Inc.
2018-03-29	Dr. Berendt, 69, has served as a Director of the Company since March 1998. Waters Committee Memberships: Audit Committee, Nominating and Corporate Governance Committee (Chair). Director Compensation Fiscal Year 2017: $296,940
2019-04-04	Dr. Berendt, 70, has served as a Director of the Company since March 1998. Dr. Berendt's experience in the pharmaceutical industry both from a management and a scientific perspective provides unique technical insight to the Waters Board. Waters Committee Memberships: Audit Committee, Science and Technology Committee. Director Compensation Fiscal Year 2018: Michael J. Berendt, Ph.D. Fees Earned or Paid in Cash $78,000, Stock Awards $109,978, Option Awards $109,995, Total $297,973.
2020-04-02	Michael J. Berendt, Ph.D. Director since 1998 Age: 71 Committees Audit Science and Technology ...Dr. Berendts experience in the pharmaceutical industry...provides unique technical insight to the Waters Board. ...Director Compensation Fiscal Year 2019 Michael J. Berendt, Ph.D. Fees Earned or Paid in Cash ($): $86,500 Stock Awards ($): $109,863 Option Awards ($): $110,000 Total ($): $306,363.